BUSINESS
Alembic Pharma’s tariff playbook: Cost cuts, complex pipeline and a supply chain armor
“Even if tariffs do come in at 5-10 percent, they can be absorbed. But anything above 25 percent could make high-volume, low-margin products unviable,” said Pranav Amin, Managing Director, Alembic Pharmaceuticals.
BUSINESS
Alembic Pharma’s June quarter profit grows 15 percent on strong US generics sales
The performance was driven by strong growth in the US generics business that saw a 13 percent year on year increase in sales.
BUSINESS
Eris Lifesciences’ profit rises 41 percent on year to Rs 125 crore, driven by domestic branded formulation growth
The company's performance was driven by robust growth in its domestic branded formulations (DBF) business and improved operating margins.
BUSINESS
Sanofi Consumer Healthcare reports 21% rise in Q2 net profit
BUSINESS
Pharma giant Eli Lilly opens strategic technology and innovation hub in Hyderabad
The US pharmaceutical giant has already hired 100 professionals and plans to expand its headcount to 1,500 in the coming years, focusing on roles in AI, automation, cloud computing, and software engineering.
BUSINESS
Aster DM-QCIL merger may complete by Q4FY26, synergies to add 10-15% to EBITDA over two years: Alisha Moopen
"The goal is micro market leadership," Alisha Moopen, Deputy Managing Director of Aster DM Healthcare, stated in a recent interview.
BUSINESS
Mankind Pharma net drops 17.4% YoY to Rs 445 crore in Q1FY26
Revenue from operations surged to ₹3,570 crore, driven by strong growth in both domestic and export businesses.
BUSINESS
Hospital chains to add 14,500 beds, spend up to Rs 32,000 crore by FY27, says ICRA
Occupancy rates are projected to remain resilient at 62–64% in FY26, while average revenue per occupied bed is expected to grow 6–8%
BUSINESS
Indian pharma exports not part of Trump's 25% tariff ambit
"The imports of drug formulations and active pharmaceutical ingredients (APIs) are currently excluded from this tariff, consistent with the April 2025 reciprocal tariff framework, where pharmaceuticals were explicitly exempted," said Maitri Sheth, Equity Research Analyst- Pharma Sector, Choice Broking.
BUSINESS
Abbott India reboots Digene: old-school antacid, new school vibe
The pharma firm is making over the famed antacid, with Digene Insta On The Go, a single-dose, water-free stick pack leading the change
BUSINESS
Burdened by over 29,000 compliances, healthcare sector seeks government intervention
A 'white paper' by the industry body NATHEALTH and EY India identifies fragmented oversight, duplicative licensing and outdated regulations as key bottlenecks stifling efficiency and innovation
BUSINESS
Dr Reddy's prioritises branded assets for strategic acquisitions: CFO Narasimham
Last year's acquisition of Haleon's global NRT business (excluding the US) for over Rs 5,000 crore, has 'exceeded' expectations, with the branded business set to expand to approximately 45 percent of its portfolio
BUSINESS
India-UK FTA set to boost pharma and medtech trade
The deal, which eliminates tariffs on most finished pharmaceutical products and medical devices, is expected to boost India’s exports to the UK valued at over $914 million grew 18% year-on-year (YoY) in FY24 . Imports from UK stood at $430.15 million with a YoY growth of 13%, according Exim data.
BUSINESS
Natco CEO says scouting for buyouts larger than Adcock to boost non-US revenue
Vice Chairman and CEO Rajeev Nannapaneni said the company is looking for another transaction, potentially as large or even larger than the Adcock deal to gain a wider geographical footprint and bring greater stability to core earnings.
BUSINESS
Natco Pharma offers to buy 35.75% stake in South Africa's Adcock Ingram for Rs 2,000 crore
Natco Pharma to set up arm in South Africa with investment of Rs 2,100 crore
BUSINESS
Apollo Hospitals eyes new international markets as Bangladesh patient flow remains muted
The company is looking at Iraq, Oman, some other Middle East countries, Southeast Asia and Africa, MD Suneeta Reddy has said
BUSINESS
Apollo Hospitals’ spin-off of digital-retail arm to unlock shareholder value; ‘mid-teen’ revenue growth expected from FY27: MD Suneeta Reddy
Reddy expects Apollo's core hospital services segment, which constitutes a little over half of the group’s revenue, to grow "mid-teens" in the next few years as new capacity comes online.
BUSINESS
IPO-bound Corona Remedies acquires cardiac, women health brands from Bayer
The acquisition includes cardiology brand Noklot and women’s healthcare brands Fostine, Luprofact, Menodac, Ovidac, Spye, and Vageston
BUSINESS
Dialysis chain NephroPlus to file papers for Rs 2,000-crore IPO this month
The proceeds from the first mainboard IPO in India’s fast-growing dialysis sector will be used to scale operations, including acquisitions of mid-sized firms in India and the Philippines
BUSINESS
Emcure in pact to market and distribute Sanofi's oral diabetes portfolio in India
The partnership will see Emcure leverage its extensive network to distribute and promote well-established Sanofi brands such as Amaryl (glimepiride) and Cetapin (metformin).
BUSINESS
Biocon Biologics gets USFDA nod for rapid-acting insulin
The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes
BUSINESS
This deal will hopefully inspire other companies to invest more in innovation: Glenn Saldanha
China has achieved a lot, largely due to immense government support. Here, it's largely the private sector
BUSINESS
Glenmark to focus on innovation and therapeutic specialisation
'We are just trying to regroup. One wrong move takes you back by four or five years,' Glenn Saldanha said, emphasising caution in deploying the AbbVie funds
BUSINESS
Glenmark to double down on innovation with multispecific antibody pipeline against cancers
Chairman and Managing Director Glenn Saldanha said on Monday that the company has several assets under development, including two disclosed candidates—ISB 2001 and ISB 2301—both emerging from its proprietary BEAT platform.
